Arcus Biosciences, Inc.

Other

Brandon Reid Rosen

Manmohan Reddy Leleti

Jay Patrick Powers

Dillon Harding Miles

Jaroslaw Kalisiak

Kenneth Victor Lawson

Erick Allen Lindsey

Ehesan Ul Sharif

Joel Worley Beatty

Debashis Mandal

Eric Newcomb

Laurent Pierre Paul Debien

Jenna Leigh Jeffrey

Juan Carlos Jaen

Guillaume Mata

Samuel Lawrie Drew

Balint Gal

Artur Karenovich Mailyan

Clayton Hardman

Matthew Epplin

Kai Yu

Rhiannon Thomas-Tran

Yongli Su

Anh Thu Tran

Zhang Wang

Steven Donald Jacob

Tezcan Guney

Karl T Haelsig

Xuelei Yan

Hyunyoung Moon

Jeremy Thomas Andre Fournier

Laurent Debien

Ehesan Ui Sharif

Jeremy Fournier

Rebecca Louise Grange

Corinne Nicole Foley

Masa Podunavac

Dongdong Liu

Ehesan U I Sharif

Laurent Pierre Debien

Eric Thomas Newcomb

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Modulators of 5'-nucleotidase, ecto and the use thereof

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Inhibitors of ARG1 and/or ARG2

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Inhibitors of adenosine 5'-nucleotidase

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compound that inhibit at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Pyridone A2R antagonists

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5&#x2032;-nucleotidase, ecto is also provided.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

A compound that is an inhibitor of at least one of the Aand Aadenosine receptors having Formula (I) and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders

Compounds of Formula I that inhibit at least one of the Aand Aadenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Growing community of inventors

San Mateo, CA, United States of America

Brandon Reid Rosen